171 related articles for article (PubMed ID: 25491280)
1. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
Ann Hematol; 2015 May; 94(5):879-80. PubMed ID: 25491280
[No Abstract] [Full Text] [Related]
2. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.
Lasho TL; Mims A; Elliott MA; Finke C; Pardanani A; Tefferi A
Leukemia; 2014 Jun; 28(6):1363-5. PubMed ID: 24445868
[No Abstract] [Full Text] [Related]
3. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
4. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
5. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
6. Changes in allele frequencies of
Nooruddin Z; Miltgen N; Wei Q; Schowinsky J; Pan Z; Tobin J; Purev E; Gutman JA; Robinson W; Pollyea DA
Haematologica; 2017 May; 102(5):e207-e209. PubMed ID: 28209656
[No Abstract] [Full Text] [Related]
7. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
9. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
10. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.
Cui Y; Li B; Gale RP; Jiang Q; Xu Z; Qin T; Zhang P; Zhang Y; Xiao Z
J Hematol Oncol; 2014 Oct; 7():77. PubMed ID: 25316523
[TBL] [Abstract][Full Text] [Related]
11. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients.
Freedman JL; Desai AV; Bailey LC; Aplenc R; Burnworth B; Zehentner BK; Teachey DT; Wertheim G
Pediatr Blood Cancer; 2016 Jan; 63(1):156-9. PubMed ID: 26274939
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
13. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
15. Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
Carratt SA; Kong GL; Curtiss BM; Schonrock Z; Maloney L; Maniaci BN; Blaylock HZ; Baris A; Druker BJ; Braun TP; Maxson JE
Blood; 2022 Aug; 140(6):644-658. PubMed ID: 35482940
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
17. Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.
Ikeda Y; Yamanouchi J; Takenaka K
Ann Hematol; 2021 Oct; 100(10):2639-2641. PubMed ID: 32676732
[No Abstract] [Full Text] [Related]
18. Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.
Ammatuna E; Eefting M; van Lom K; Kavelaars FG; Valk PJ; Touw IP
Ann Hematol; 2015 Jun; 94(6):1079. PubMed ID: 25821085
[No Abstract] [Full Text] [Related]
19. Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature.
Wang L; Du F; Zhang HM; Wang HX
Braz J Med Biol Res; 2015 Jul; 48(7):583-7. PubMed ID: 26017341
[TBL] [Abstract][Full Text] [Related]
20. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]